2. Захаров В.В., Яхно Н.Н. Синдромы нарушения высших психических функций. Болезни нервной системы. Руководство для врачей. Под ред. Н.Н. Яхно. М., 2005, Т. 1. С. 170–89.

3. Захаров В.В., Кабаева А.Р. Недементные когнитивные нарушения: субъективные, легкие и умеренные. Нервные болезни. 2017;4;3–9.

4. Остроумова О.Д., Черняева М.С. Антигипертензивные препараты в профилактике когнитивных нарушений и деменции: фокус на антагонисты кальция и диуретики. Кардиоваскулярная терапия и профилактика. 2018;17(5):79–91.

5. Федин А.И. Артериальная гипертензия и когнитивные нарушения. Взгляд невролога. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;123(11):1–7.

6. Остроумова О.Д., Парфенов В.А., Остроумова Т.М. и др. Консенсус экспертов. влияние антигипертензивной терапии на когнитивные функции. Системные гипертензии. 2021;18(1):5–12.

7. Ungvari Z., Toth P., Tarantini S., et al. Hypertension-induced cognitive impairment: from pathophysiology to public health. Nature reviews. Nephrol. 2021;17(10):639–54. Doi: 10.1038/s41581-021-00430-6.

8. Левин О.С., Боголепова А.Н., Лобзин В.Ю. Общие механизмы патогенеза нейроденеративных и цереброваскулярных заболеваний и возможности их коррекции. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(5):11.

9. Ушкалова Е.А., Ткачева О.Н., Рунихина Н.К. и др. Особенности фармакотерапии у пожилых пациентов. Введение в проблему. Рациональная фармакотерапия в кардиологии. 2016;12 (1):94–100.

10. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet. Public health. 2022;7(2):105–25. Doi: 10.1016/S2468-2667(21)00249-8.

11. Livingston G., Huntley J., Sommerlad A., et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–46.

12. Parfenov V.A., Ostroumova T.M., Pеrepelova E.M., et al. Brain perfusion, cognitive functions, and vascular age in middle aged patients with essential arterial hypertension. Сardiol. 2018;(5):23–31.

13. Fryar C.D., Ostchega Y., Hales C.M., et al. Hypertension Prevalence and Control among Adults: United States 2015–1026. NCHS Data Brief. 2017;(289):1–8.

14. Lloyd‐Jones D.M., Evans J.C., Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005;294(4):466–72. Doi: 10.1001/jama.294.4.466..

15. Franklin S.S., Larson M.G., Khan S.A., et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulat. 2001;103(9):1245–49. Doi: 10.1161/01.cir.103.9.1245.

16. Бойцов С.А., Баланова Ю.А., Шальнова С.А. и др. Артериальная гипертония среди лиц 25–64 лет: распространенность, осведомленность, лечение и контроль по материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;13(4):4–14.

17. Ерина А.М., Ротарь О.П., Солнцев В.Н. и др. Эпидемиология артериальной гипертензии в Российской Федерации – важность выбора критериев диагностики. Кардиология. 2019;59(6):5–11.

18. Парфенов В.А., Старчина Ю.А. Когнитивные нарушения у пациентов с артериальной гипертензией и их лечение. Неврология, нейропсихиатрия, психосоматика. 2011;(1):27–33.

19. Iadecola C., Yaffe K., Biller J., et al., & American Heart Association Council on Hypertension; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Stroke Council. Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association. Hypertension (Dallas, Tex.: 1979). 2016;68(6):e67–94. Doi: 10.1161/HYP.0000000000000053.

20. Клинические рекомендации «Артериальная гипертензия у взрослых». Год утверждения: 2020.

21. Ostroumova T.M., Parfenov V.A., Ostroumova O.D. Hypertension and cognitive impairment: the standpoint of evidence-based medicine. Neurol Neuropsych Psychosomat. 2017;9(4):70–6. Doi: 10.14412/2074-2711-2017-4-70-76.

22. Gottesman R.F., Schneider A.L., Albert M., et al. Midlife hypertension and 20-year cognitive change: the Atherosclerosis Risk in Communities neurocognitive study. JAMA. Neurol. 2014;71:1218–27.1. Doi: 10.1001/jamaneurol.2014.1646.

23. Elias M.F., Wolf P.A., D’Agostino R.B., et al. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol. 1993;138(6):353–64. Doi: 10.1093/oxfordjournals.aje.a116868.

24. Launer L.J., Ross G.W., Petrovitch H., et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol. Aging. 2000;21(1):49–55. Doi: 10.1016/s0197-4580(00)00096-8.

25. Kohler S., Baars M. A., Spauwen P., et al. Temporal evolution of cognitive changes in incident hypertension: prospective cohort study across the adult age span. Hypertension (Dallas, Tex.: 1979). 2014;63(2):245–51. Doi: 10.1161/HYPERTENSIONAHA.113.02096.

26. Skoog I., Lernfelt B., Landahl S., et al. 15-year longitudinal study of blood pressure and dementia. Lancet (London, England). 1996;347(9009):1141–45. Doi: 10.1016/s0140-6736(96)90608-x.

27. Elias P.K., Elias M.F., Robbins M.A., et al. Blood pressure-related cognitive decline: does age make a difference? Hypertension (Dallas, Tex.: 1979). 2004;44(5):631–36. Doi: 10.1161/01.HYP.0000145858.07252.99.

28. Ou Y.N., Tan C.C., Shen X.N., et al. Blood Pressure and Risks of Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis of 209 Prospective Studies. Hypertension (Dallas, Tex.: 1979). 2020;76(1):217–25. Doi: 10.1161/HYPERTENSIONAHA.120.14993.

29. Peters R., Xu Y., Fitzgerald O., et al. Dementia rIsk REduCTion (DIRECT) collaboration. Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis. Eur Heart J. 2022;43(48):4980–90. Doi: 10.1093/eurheartj/ehac584.

30. Tzourio C., Dufouil C., Ducimetiere P., Alperovitch A. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging. Neurol. 1999;53(9):1948–52. Doi: 10.1212/wnl.53.9.1948.

31. Staessen J.A., Fagard R., Thijs L., et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757–64. Doi: 10.1016/S0140-6736(97)05381-6.

32. Tzourio C., Anderson C., Chapman N., et al.; PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Int Med. 2003;163(9):1069–75. Doi: 10.1001/archinte.163.9.1069.

33. SPRINT MIND Investigators for the SPRINT Research Group, Williamson J.D., Pajewski N.M., Auchus A.P et al. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA. 2019;321(6):553–61. Doi: 10.1001/jama.2018.21442.

34. Diener H.-C., Sacco R.L., Yusuf S., et al. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet. Neurol. 2008;7:875–84. Doi: 10.1016/S1474-4422(08)70198-4.

35. Applegate W.B., Pressel S., Wittes J., et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med. 1994;154:2154–60.

36. Peters R., Beckett N., Forette F., et al. Incident dementia and blood pressure lowering in the hypertension in the very elderly trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet. Neurol. 2008;7:683–89. Doi: 10.1016/S1474-4422(08)70143-1.

37. Anderson C., Teo K., Gao P., et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet. Neurol. 2011;10:43–53. Doi: 10.1016/S1474-4422(10)70250-7.

38. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ. (Clinical research ed.). 1992;304(6824):405–12. Doi: 10.1136/bmj.304.6824.405.

39. Levi Marpillat N., Macquin-Mavier I., Tropeano A.I., et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens. 2013;31(6):1073–82. Doi: 10.1097/HJH.0b013e3283603f53.

40. Fournier A., Oprisiu-Fournier R., Serot J.M., et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE- inhibitors. Exp Rev Neurother. 2009;9(9):1413–31.

41. Yasar S., Schuchman M., Peters J., et al. Relationship Between Antihypertensive Medications and Cognitive Impairment: Part I. Review of Human Studies and Clinical Trials. Curr Hypertens Rep. 2016;18(8):67.

42. Peters R., et al. Antihypertensive drug use and risk of cognitive decline in the very old: an observational study – the Newcastle 85+ Study. J Hypertens. 2015;33(10):2156–64.

43. Trompet S., et al. Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study. Neurobiol. Aging. 2008;29(2):306–8.

44. Peters R., Booth A., Peters J. A systematic review of calcium channel blocker use and cognitive decline/dementia in the elderly. J Hypertens. 2014;32:1945–57.

45. Paris D., Bachmeier C., Patel N., et al. Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier. Mol Med. (Cambridge, Mass.). 2011;17(3–4):149–62. Doi: 10.2119/molmed.2010.00180.

46. Li Y., Ying-Xin Y., Ming L. The PDC bit cutter working angle of transverse vibration drilling mode calculation. Nat Gas Industry. 2008;28(3):72–4.

47. Toescu E.C., Verkhratsky A. The importance of being subtle: Small changes in calcium homeostasis control cognitive decline in normal aging. Aging Cell. 2007;6(3):267–73. Doi: 10.1111/j.1474-9726.2007.00296.x.

48. Guo Q., Christakos S., Robinson N., Mattson M.P. Calbindin D28k blocks the proapoptotic actions of mutant presenilin 1: Reduced oxidative stress and preserved mitochondrial function. Proceed National Acad Sci. 1998;95(6):3227–32. Doi: 10.1073/pnas.95.6.3227.

49. LaFerla F.M. Calcium dyshomeostasis and intracellular signalling in Alzheimer’s disease. Nature reviews. Neurosci. 2002;3(11)6:862–72. Doi: 10.1038/nrn960.

50. Bachmeier C., Beaulieu-Abdelahad D., Mullan M. Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier. Eur. J. Pharmacol. 2011;659(2–3):124–29. Doi: 10.1016/j.ejphar.2011.03.048.

51. Yasar S., Corrada M., Brookmeyer R., Kawas C. Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging. Neurobiol. Aging. 2005;26(2):157–63. Doi: 10.1016/j.neurobiolaging.2004.03.009.

52. Forette F., Seux M.L., Staessen J.A., et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet (London, England). 1998;352(9137):1347–51. Doi: 10.1016/s0140-6736(98)03086-4.

53. Forette F., Seux M.-L., Staessen J.A., et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162(18):2046–52. Doi: 10.1001/archinte.162.18.2046.

54. Wang J.G., Staesse J.A., Gong L., Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Int Med. 2000;160(2):211–20. Doi: 10.1001/archinte.160.2.211.

55. Яскевич Р.А., Кочетков А.И., Остроумова О.Д. и др. Оценка влияния нитрендипина на когнитивный статус больных старших возрастных групп с артериальной гипертонией. Сборник тезисов. XIII Международный конгресс «Кардиология на перекрестке наук». 2023. С. 384–87.

56. Tully P.J., Hanon O., Cosh S., Tzourio C. Diuretic antihypertensive drugs and incident dementia risk: a systematic review, meta-analysis and meta-regression of prospective studies. J Hypertens. 2016;34(6):1027–35. Doi: 10.1097/HJH.0000000000000868.

57. Lu M., Ma L., Wang X., et al. Indapamide suppresses amyloid-β production in cellular models of Alzheimer’s disease through regulating BACE1 activity. Int J Clin Exp Med. 2017;10(4):5922–30.

58. Chillon J.M., Baumbach G.L. Effects of indapamide, a thiazide-like diuretic, on structure of cerebral arterioles in hypertensive rats. Hypertension. 2004;43(5):1092–97. Doi: 10.1161/01.HYP.0000122874.21730.81.

59. Chen P., Chaugai S., Zhao F., Wang D.W. Cardioprotective Effect of Thiazide-Like Diuretics: A Meta-Analysis. Am J Hypertens. 2015;28(12):1453–63. Doi: 10.1093/ajh/hpv050.

60. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet (London, England). 2001;358(9287):1033–41. Doi: 10.1016/S0140-6736(01)06178-5.

61. PATS Collaborating Group.Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J. (Engl). 1995;108(9):710–7.